Home Transmembrane Transporters Amino acid transporter inhibitor Nanvuranlat (JPH203)

Nanvuranlat (JPH203)

Catalog No.S8667 Synonyms: KYT-0353, JPH-203SBECD

For research use only.

Nanvuranlat (JPH203, KYT-0353, JPH-203SBECD), a selective L-type amino acid transporter 1 inhibitor, shows a dramatic inhibition of leucine uptake (IC50=0.06 µM) and cell growth (IC50=4.1 µM) in human colon cancer cells (HT-29), human oral cancer cells (YD-38) and leukemic cells.

Nanvuranlat (JPH203) Chemical Structure

CAS No. 1037592-40-7

Selleck's Nanvuranlat (JPH203) has been cited by 11 Publications

Purity & Quality Control

Choose Selective Amino acid transporter Inhibitors

Related Compound Libraries

Biological Activity

Description Nanvuranlat (JPH203, KYT-0353, JPH-203SBECD), a selective L-type amino acid transporter 1 inhibitor, shows a dramatic inhibition of leucine uptake (IC50=0.06 µM) and cell growth (IC50=4.1 µM) in human colon cancer cells (HT-29), human oral cancer cells (YD-38) and leukemic cells.
Targets
LAT1 [1]
(Cell-free assay)
In vitro

JPH203 completely and slightly inhibited the L-Leucine uptake in YD-38 cells (IC50 value: 0.79 μM) and NHOKs (IC50 value: >100 μM), respectively. JPH203 inhibited HT-29 cell growth, generating an apparent IC50 of 4.1 μM, but the JPH203 IC50 concentration (0.06 μM) needed to inhibit the L-Leucine uptake did not inhibit HT-29 cell growth, which represents a 68-fold difference in susceptibility[1]. JPH203 activated the mitochondria-dependent apoptotic signaling pathway by upregulating pro-apoptotic factors, such as Bad, Bax, and Bak, and the active form of caspase-9, and downregulating anti-apoptotic factors, such as Bcl-2 and Bcl-xL in Saos2 human osteosarcoma cells. JPH203 can distinguish relative abundance between LAT1 and LAT2. It has high selectivity for LAT1[2]. JPH203 was metabolically stable in mouse, rat, dog, monkey and human liver microsomal incubations[3]. JPH203 induces both G2/M and G0/G1 cell cycle arrest, as well as reduced the S phase accompanied by altered expression of the proteins in cell cycle progression: cyclin D1, CDK4, and CDK6[4].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MXHGeY5kfGmxbjDhd5NigQ>? M2HuO|EhcHJ? MX\Jcohq[mm2aX;uJI9nKFtzNFPdMWwudGW3Y3nu[UB2eHSja3WgZZQhVEGWMTDpckBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjCxJIhzKGK7IHzpdZVq\CC|Y3nueIltdGG2aX;uJINwfW62aX7nMEBKSzVyPUCuNFbPxE1w NFPRfpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{K1N|k5QSd-MkeyOVM6QDl:L3G+
YD-38 NWS1NnhsTnWwY4Tpc44h[XO|YYm= NUHaOlRUOSCqch?= M2HudmlvcGmkaYTpc44hd2ZiW{G0R30uVC2uZYXjbY5mKHWydHHr[UBifCCOQWSxJIlvKGi3bXHuJHlFNTN6IHPlcIx{KGGodHXyJFEhcHJiYomgcIlyfWmmIIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUC9NE44Qc7:TT6= NHPyNVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{K1N|k5QSd-MkeyOVM6QDl:L3G+
HT-29 NGrIS5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVS5OkBpenN? NG\BbmxIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxteyCvZXHzeZJm\CCjZoTldkA6PiCqcoOgZpkhS2:3bITldkBkd3WwdHXyJIJie2WmIHPlcIwh[2:3boTpcochdWW2aH;kMEBKSzVyPUSuNe69VS5? M2HLOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkWzPVg6Lz5{N{K1N|k5QTxxYU6=
Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot p53 / Bad / Bcl-2 / Bcl-xl / Bax / Bak / Cleaved caspase / Cleaved PARP ; p70S6K / p-P70S6k / p-S6 / S6 / p-ERK / ERK / p-AKT / AKT' ; p-GCN2 / GCN2 / p-EIF2α / EIF2α / ATF4 29200902 30241549 30784173
Growth inhibition assay Cell viability 29200902
In vivo Daily intravenous administration of JPH203 (12.5 and 25 mg/kg) significantly inhibited tumor growth in KKU-213 cholangiocarcinoma cell xenografts in the nude mice model in a dose-dependent manner with no statistically significant change in the animal’s body weight and with no differences in the histology and appearance of the internal organs compared with the control group. Thus, JPH203 shows anti-tumor efficacy in nude mice bearing human cholangiocarcinom (CCA) cell xenografts without general toxicity[4].

Protocol (from reference)

Cell Research:

[2]
  • Cell lines: Saos2 human osteosarcoma cells
  • Concentrations: 100 µM
  • Incubation Time: 72 h
  • Method:

    Colony formation assays are performed by seeding 300 cells/well into 6 well plates. After 24 h of growth, the cells are treated with 100 µM JPH203 for 72 h. The JPH203 treatment is removed and fresh medium is added. The cells are incubated for 10 days. Thereafter, medium is removed and the cells are washed with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde for 10 min at 4℃. Sequentially, the colonies are stained with 2% crystal violet for 10 min. Finally, colonies stained by crystal violet are washed with PBS and dried at room temperature, before imaged by a digital camera.
Animal Research:

[3]
  • Animal Models: Sprague-Dawley rats
  • Dosages: 0.9-1.0 mg/kg
  • Administration: i.v.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 472.32
Formula

C23H19Cl2N3O4
CAS No. 1037592-40-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC=C(C=C1)C2=NC3=CC(=CC(=C3O2)COC4=C(C=C(C=C4Cl)CC(C(=O)O)N)Cl)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Nanvuranlat (JPH203) | Nanvuranlat (JPH203) supplier | purchase Nanvuranlat (JPH203) | Nanvuranlat (JPH203) cost | Nanvuranlat (JPH203) manufacturer | order Nanvuranlat (JPH203) | Nanvuranlat (JPH203) distributor